Clinuvel Pharmaceuticals Limited (CUVL)

Clinuvel Pharmaceuticals Revenue

In the fiscal year ending June 30, 2026, Clinuvel Pharmaceuticals had annual revenue of 94.02M AUD, down -1.05%. Clinuvel Pharmaceuticals had revenue of 57.09M in the half year ending June 30, 2026, with 3.10% growth.

• Revenue (ttm): 94.02M AUD
• Revenue Growth: -1.05%
• P/S Ratio: 3.90
• Revenue / Employee: 5,876,525 AUD
• Employees: 16
• Market Cap: 253.61M USD

Revenue Chart

Chart

Chart

* This company reports financials in AUD.

Revenue by Geography

Chart

• Ireland 52.51M 55.8%
• United States 40.73M 43.3%
• Rest of The World 791.00K 0.8%

Fiscal year ended Jun 30, 2026 See the full Clinuvel Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	94.02M	-993.17K	-1.05%
Jun 30, 2025	95.02M	6.84M	7.76%
Jun 30, 2024	88.18M	9.86M	12.59%
Jun 30, 2023	78.32M	12.60M	19.17%
Jun 30, 2022	65.72M	17.40M	36.02%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 11, 2026

Data Sources Report a data error